読み込み中
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
前日終値
$4.22
+$0.04 · +0.96%
日中の時刻はETです。市場データは遅延する場合があります。
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
日中レンジ
現在 $4.22
52週レンジ
現在 $4.22
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
87
大幅な割安
センチメント
54
まちまち
リスク
33
中程度のリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
日中レンジ
現在 $4.22
52週レンジ
現在 $4.22
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1408.3万 USD | 617.1万 USD | 1814.1万 USD | 3901.9万 USD | 1098.8万 USD |
| 売上原価 | 36.3万 USD | — | — | — | — |
| 粗利益 | 1372万 USD | 617.1万 USD | 1814.1万 USD | 3901.9万 USD | 1098.8万 USD |
| 研究開発 | 2524.1万 USD | 5403.7万 USD | 7370万 USD | 8440.8万 USD | 6550.2万 USD |
| 販売・一般管理 | 1589.3万 USD | 2210.8万 USD | 2247.5万 USD | 1783.4万 USD | 1713.6万 USD |
| 営業費用 | 4077.1万 USD | 8249万 USD | 9624.4万 USD | 1.04億 USD | 8451万 USD |
| 受取利息 | 406.8万 USD | 658.5万 USD | 568.8万 USD | 219.2万 USD | 12.7万 USD |
| 支払利息 | 9.7万 USD | 13.7万 USD | 45.9万 USD | 172.6万 USD | 285.7万 USD |
| 減価償却費と償却費 | 36.3万 USD | 138万 USD | 140.4万 USD | 142.7万 USD | 175.3万 USD |
| 営業利益 | −2705.1万 USD | −7631.9万 USD | −7810.3万 USD | −6545.6万 USD | −7352.2万 USD |
| 純利益 | −3350.1万 USD | −6992万 USD | −7284.9万 USD | −6945.6万 USD | −7624.7万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.50
上昇余地（101.42%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
